tirzepatide gets warm Left Out Warm? Heat Damage Risk Explained Inject Tirzepatide Cold? Storage &

10.1021/acsami.7b08700 122 YangC.LiuY.HeY.DuY.WangW.ShiX.et al (2013)

These predispositions should be interpreted with a qualified healthcare provider as part of a broader assessment

NDIN applies to ingredients not marketed in the US before 1994

Final Verdict: 7 Clinical Facts Ozempic is not licensed for weight loss in the UK Wegovy is the licensed semaglutide weight management product Mounjaro and Wegovy are different drugs tirzepatide (dual GLP-1/GIP) vs semaglutide (GLP-1 only) In the SURMOUNT-5 head-to-head trial, Mounjaro produced 20.2% vs Wegovys 13.7% average weight loss Wegovy is approximately 75/month cheaper at Slinic maintenance doses important for cost-sensitive patients Wegovy has the NICE cardiovascular indication (April 2026) Mounjaro does not yet have this label Wegovy now has a licensed oral version (MHRA June 2026) Mounjaro does not yet have an oral equivalent Neither Ozempic off-label nor compounded alternatives are appropriate when licensed products are readily available from a GPhC-registered UK pharmacy Slinic prescribes Mounjaro and Wegovy both correctly licensed, both from Eli Lilly and Novo Nordisk authorised supply chains, both reviewed by a registered UK prescriber

Age compounds the problem

AMG 133 chemical structure